Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds (Q11201): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
||
| Property / financed by | |||
| Property / financed by: Directorate-General for Regional and Urban Policy / rank | |||
Revision as of 15:36, 28 October 2020
Project Q11201 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds |
Project Q11201 in Czech Republic |
Statements
5,769,000.0 Czech koruna
0 references
15,384,000.0 Czech koruna
0 references
37.5 percent
0 references
12 May 2017
0 references
17 April 2020
0 references
VUAB Pharma a.s.
0 references
50°9'46.91"N, 14°23'2.26"E
0 references
25263
0 references
Předmětem projektu je vývoj postupu přípravy vysoce účinných proteolytik (KR-X) z antarktického krillu, které budou použity v různých oborech medicíny. Výstupem, kromě technologických postupů přípravy, budou dva prototypy proteolytika KR-X - pro léčbu chronických ran a pro trombolýzu cévních trombů. Díky mechanismu působení enzymu na nežádoucí fibrin a fragmenty se předpokládá u pacientů lepší snášenlivost a nižší bolestivost léčby oproti agresívnějším enzymatickým prostředkům. a. (Czech)
0 references
The subject of the project is the development of the process of preparation of highly effective proteolytics (KR-X) from Antarctic krill, which will be used in various fields of medicine. The output, in addition to technological procedures of preparation, will be two prototypes of KR-X proteolytic – for the treatment of chronic wounds and for thrombolysis of vascular thrombs. Due to the mechanism of action of the enzyme on undesirable fibrin and fragments, patients are expected to be more tolerable and less painful than more aggressive enzymatic agents. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/16_083/0010108
0 references